bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Tables from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Authors: Xu Xiaowei , De Angelis Carmine , Burke Kathleen A. , Nardone Agostina , Hu Huizhong , Qin Lanfang , Veeraraghavan Jamunarani , Sethunath Vidyalakshmi , Heiser Laura M. , Wang Nicholas , Ng Charlotte K.Y. , Chen Edward S. , Renwick Alexander , Wang Tao , Nanda Sarmistha , Shea Martin , Mitchell Tamika , Rajendran Mahitha , Waters Ian , Zabransky Daniel J. , Scott Kenneth L. , Gutierrez Carolina , Nagi Chandandeep , Geyer Felipe C. , Chamness Gary C. , Park Ben H. , Shaw Chad A. , Hilsenbeck Susan G. , Rimawi Mothaffar F. , Gray Joe W. , Weigelt Britta , Reis-Filho Jorge S. , Osborne C. Kent , Schiff Rachel
Published: April 2023

Supplementary tables S1-S4
Supplementary Figures 1 & 2 from A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy
Authors: Sayyid Rashid K. , Evans Andrew , Hersey Karen , Maloni Ranjena , Hurtado-Coll Antonio , Kulkarni Girish , Finelli Antonio , Zlotta Alexandre R. , Hamilton Robert , Gleave Martin , Fleshner Neil E.
Published: April 2023

Supplementary Figure 1. Immunohistochemical expression of Ki-67 after degarelix, degarelix and bicalutamide, or LHRH agonist and bicalutamide. (ONLINE ONLY) Supplementary Figure 2. Immunohistochemical expression of alpha-methylacyl-CoA racemase (AMACR) after degarelix, degarelix and bicalutamide, or LHRH agonist and bicalutamide. (ONLINE ONLY)
Supplementary Figures from HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer
Authors: Xu Xiaowei , De Angelis Carmine , Burke Kathleen A. , Nardone Agostina , Hu Huizhong , Qin Lanfang , Veeraraghavan Jamunarani , Sethunath Vidyalakshmi , Heiser Laura M. , Wang Nicholas , Ng Charlotte K.Y. , Chen Edward S. , Renwick Alexander , Wang Tao , Nanda Sarmistha , Shea Martin , Mitchell Tamika , Rajendran Mahitha , Waters Ian , Zabransky Daniel J. , Scott Kenneth L. , Gutierrez Carolina , Nagi Chandandeep , Geyer Felipe C. , Chamness Gary C. , Park Ben H. , Shaw Chad A. , Hilsenbeck Susan G. , Rimawi Mothaffar F. , Gray Joe W. , Weigelt Britta , Reis-Filho Jorge S. , Osborne C. Kent , Schiff Rachel
Published: April 2023

Supplementary Figures S1-S8
Supplementary Tables 1-3, Supplementary Figure 1-2 from Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer
Authors: Labidi-Galy S. Intidhar , Olivier Timothée , Rodrigues Manuel , Ferraioli Domenico , Derbel Olfa , Bodmer Alexandre , Petignat Patrick , Rak Beata , Chopin Nicolas , Tredan Olivier , Heudel Pierre-Etienne , Stuckelberger Sarah , Meeus Pierre , Meraldi Patrick , Viassolo Valeria , Ayme Aurélie , Chappuis Pierre O. , Stern Marc-Henri , Houdayer Claude , Stoppa-Lyonnet Dominique , Buisson Adrien , Golmard Lisa , Bonadona Valérie , Ray-Coquard Isabelle
Published: April 2023

Table S1: Multivariate Model of progression-free survival in the study cohort; Table S2: Multivariate Model of overall survival in the study cohort; Table S3: BRCA2 mutations in the study cohort; Figure S1: Flow diagram for selection of patients in the study cohort; Figure S2: A model for double-strand breaks repair by homologous recombination that depends on the location of mutation in BRCA2 gene.
Supplementary information from Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against Cancer
Authors: Mameri Hamza , Bièche Ivan , Meseure Didier , Marangoni Elisabetta , Buhagiar-Labarchède Géraldine , Nicolas André , Vacher Sophie , Onclercq-Delic Rosine , Rajapakse Vinodh , Varma Sudhir , Reinhold William C. , Pommier Yves , Amor-Guéret Mounira
Published: April 2023

Supplementary Figure Legends, Supplementary Table Legends, Supplementary Material Legends
Supplementary figure legends from miRNA-487a Promotes Proliferation and Metastasis in Hepatocellular Carcinoma
Authors: Chang Rui-Min , Xiao Shuai , Lei Xiong , Yang Hao , Fang Feng , Yang Lian-Yue
Published: April 2023

Supplementary figure legends for Figure S1-S14
Supplemental Table 1 from BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer
Authors: Benson Al B. , Kiss Igor , Bridgewater John , Eskens Ferry A.L.M. , Sasse Carolyn , Vossen Sandra , Chen Jihong , Van Sant Chip , Ball Howard A. , Keating Anne , Krivoshik Andrew
Published: April 2023

Baseline Patient Characteristics: Serum Biomarker Analysis Group
Supplementary material from Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers
Authors: Fujii Takeo , Barzi Afsaneh , Sartore-Bianchi Andrea , Cassingena Andrea , Siravegna Giulia , Karp Daniel D. , Piha-Paul Sarina A. , Subbiah Vivek , Tsimberidou Apostolia M. , Huang Helen J. , Veronese Silvio , Di Nicolantonio Federica , Pingle Sandeep , Vibat Cecile Rose T. , Hancock Saege , Berz David , Melnikova Vladislava O. , Erlander Mark G. , Luthra Rajyalakshmi , Kopetz E. Scott , Meric-Bernstam Funda , Siena Salvatore , Lenz Heinz-Josef , Bardelli Alberto , Janku Filip
Published: April 2023

Supplementary methods. Supplementary Table S1. Verification of the analytical sensitivity (lower limit of detection) of the KRASG12/G13 mutation-enrichment NGS assay. Supplementary Table S2. KRASG12/G13 mutations in archival tumor tissue, urine cell-free DNA (cfDNA) and plasma cfDNA. Supplementary Table S3. Systemic therapies in patients with serial urine and/or plasma cell-free DNA (cfDNA) collection. Supplementary Figure S1. Workflow and characteristics of the platform used to analyze cell-free DNA in urine and plasma. Supplementary Figure S2. Schematic of the mutation-enrichment next-generatin sequencing (NGS) assay for the detection of KRASG12/13 mutations in cell-free DNA (cfDNA). Supplementary Figure S2. Schematic of the mutation-enrichment next-generatin sequencing (NGS) assay for the detection of KRASG12/13 mutations in cell-free DNA (cfDNA). Supplementary Figure S3. Kaplan-Meier curves of overall survival (OS) based on the number of KRASG12/13 copies in cell-free DNA (cfDNA). Supplementary Figure S4. Kaplan-Meier curves of overall survival (OS) based on the concentration of cell-free DNA (cfDNA).
Supplemental Table 1 from A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Authors: Zhang Yi , Schroeder Brock E. , Jerevall Piiha-Lotta , Ly Amy , Nolan Hannah , Schnabel Catherine A. , Sgroi Dennis C.
Published: April 2023

Supplemental Table 1 shows the clinical and pathologic characteristics for patients with early vs late distant recurrences.
Table S1 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

Characterization of anti-CDH17 RGD mAbs
Supplemental Figure 5 from A Novel Breast Cancer Index for Prediction of Distant Recurrence in HR+ Early-Stage Breast Cancer with One to Three Positive Nodes
Authors: Zhang Yi , Schroeder Brock E. , Jerevall Piiha-Lotta , Ly Amy , Nolan Hannah , Schnabel Catherine A. , Sgroi Dennis C.
Published: April 2023

Supplemental Figure 5 shows the prognostic performance of BCIN+ for overall 15-year and late post-5-year distant recurrence in subsets of patients with differing numbers of positive nodes.
Figure S3 from Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis
Authors: Bartolomé Rubén A. , Aizpurua Carmen , Jaén Marta , Torres Sofía , Calviño Eva , Imbaud Juan I. , Casal J. Ignacio
Published: April 2023

Breast cancer and melanoma cell lines do not express CDH17
Supplementary Fig. S1-S6 from Intravaginal Administration of Fc-Fused IL7 Suppresses the Cervicovaginal Tumor by Recruiting HPV DNA Vaccine-Induced CD8 T Cells
Authors: Choi Young Woo , Kang Moon Cheol , Seo Yong Bok , Namkoong Hong , Park Yunji , Choi Dong-Hoon , Suh You Suk , Lee Seung-Woo , Sung Young Chul , Jin Hyun-Tak
Published: April 2023

Supplementary Figure 1. Schematic diagram of Fc-fused IL-7 Supplementary Figure 2. FcRn-mediated transcytosis and transport of Fc-fused IL-7 into serum after intravaginal treatment Supplementary Figure 3. Distinct localization patterns of CD4 and CD8 T cells after intravaginal administration of IL-7-Fc Supplementary Figure 4. Comparison of Fc-fragment and IL-7-Fc on accumulation of T cells in cervicovaginal tissue Supplementary Figure 5. Abrogation of T cell accumulation after IL-7RÃŽ{plus minus} blocking Supplementary Figure 6. Route-dependency of IL-7-Fc administration on recruitment of T cells in cervicovaginal tissue
supplementary methods and legends from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

This file contains the supplementary methods that either describe the methodological part related to supplementary figures or the detailed aspects for the following methods: clustering, pathway analysis, survival, methylation and proteomic analyses, and cell line drug response analyses. The file also includes the legends for all supplementary data (Figures and Tables).
supplementary Table S5 from BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Authors: Barras David , Missiaglia Edoardo , Wirapati Pratyaksha , Sieber Oliver M. , Jorissen Robert N. , Love Chris , Molloy Peter L. , Jones Ian T. , McLaughlin Stephen , Gibbs Peter , Guinney Justin , Simon Iris M. , Roth Arnaud D. , Bosman Fred T. , Tejpar Sabine , Delorenzi Mauro
Published: April 2023

Analysis of GO processes enriched in several mTOR signatures.
Supplementary Table S5 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Table summarizing the 16 significant biomarkers selected for qPCR validation in urine samples, which were overexpressed in cancer samples compared to control samples based on the standard differential analysis of the RNA-seq data and underexpressed in blood cells based on the gene expression profiling data in the human hematopoietic system in gene expression commons platform.
Supplementary Table S3 from Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics
Authors: Sin Mandy L.Y. , Mach Kathleen E. , Sinha Rahul , Wu Fan , Trivedi Dharati R. , Altobelli Emanuela , Jensen Kristin C. , Sahoo Debashis , Lu Ying , Liao Joseph C.
Published: April 2023

Full list of differentially expressed genes identified in comparison of the 3 LG bladder cancer urine samples to 8 control urine samples based on urinary RNA-seq data in the urinary biomarker discovery.
Supplemental Table 1-3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells
Authors: Ozawa Hiroyuki , Ranaweera Ruchira S. , Izumchenko Evgeny , Makarev Eugene , Zhavoronkov Alex , Fertig Elana J. , Howard Jason D. , Markovic Ana , Bedi Atul , Ravi Rajani , Perez Jimena , Le Quynh-Thu , Kong Christina S. , Jordan Richard C. , Wang Hao , Kang Hyunseok , Quon Harry , Sidransky David , Chung Christine H.
Published: April 2023

Supplemental Table 1. Summary of patient characteristics with newly diagnosed HNSCC. Supplemental Table 2. Summary of patient characteristics with recurrent and/or metastatic HNSCC. Supplemental Table 3. Injection of FaDu-SMAD4 cells results in lower take rate in mice compared to the control cell line and shows no signs of metastatic lesion.
Supplemental Figures 1-2 from Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Authors: Pili Roberto , Quinn David I. , Hammers Hans J. , Monk Paul , George Saby , Dorff Tanya B. , Olencki Thomas , Shen Li , Orillion Ashley , Lamonica Dominick , Fragomeni Roberto S. , Szabo Zsolt , Hutson Alan , Groman Adrienne , Perkins Susan M. , Piekarz Richard , Carducci Michael A.
Published: April 2023

Supplemental Figure 1. Tumor infiltrating Treg; Supplemental Figure 2. Treg and IFNï�§-CD8.
Supplemental Figure Legend from Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Authors: Pili Roberto , Quinn David I. , Hammers Hans J. , Monk Paul , George Saby , Dorff Tanya B. , Olencki Thomas , Shen Li , Orillion Ashley , Lamonica Dominick , Fragomeni Roberto S. , Szabo Zsolt , Hutson Alan , Groman Adrienne , Perkins Susan M. , Piekarz Richard , Carducci Michael A.
Published: April 2023

Supplemental Figure Legend
Table S2 from Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
Authors: Joung Je-Gun , Oh Bo Young , Hong Hye Kyung , Al-Khalidi Hisham , Al-Alem Faisal , Lee Hae-Ock , Bae Joon Seol , Kim Jinho , Cha Hong-Ui , Alotaibi Maram , Cho Yong Beom , Hassanain Mazen , Park Woong-Yang , Lee Woo Yong
Published: April 2023

Supplementary Table S2. Transition types of clonality and mutation prifiles in CRC patients
Table S1 from Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer
Authors: Joung Je-Gun , Oh Bo Young , Hong Hye Kyung , Al-Khalidi Hisham , Al-Alem Faisal , Lee Hae-Ock , Bae Joon Seol , Kim Jinho , Cha Hong-Ui , Alotaibi Maram , Cho Yong Beom , Hassanain Mazen , Park Woong-Yang , Lee Woo Yong
Published: April 2023

Supplementary Table S1. Read mapping information of CRC samples
Supplementary Table 12 from Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Authors: Liu Hao , Naxerova Kamila , Pinter Matthias , Incio Joao , Lee Hang , Shigeta Kohei , Ho William W. , Crain Jonathan A. , Jacobson Alex , Michelakos Theodoros , Dias-Santos Daniella , Zanconato Andrea , Hong Theodore S. , Clark Jeffrey W. , Murphy Janet E. , Ryan David P. , Deshpande Vikram , Lillemoe Keith D. , Fernandez-del Castillo Carlos , Downes Michael , Evans Ronald M. , Michaelson James , Ferrone Cristina R. , Boucher Yves , Jain Rakesh K.
Published: April 2023

Adjusted Analysis with Multivariate Model on TCGA PDAC dataset to test for independent factors.
Supplementary Figure S2 from Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Authors: Sagawa Morihiko , Ohguchi Hiroto , Harada Takeshi , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Kizaki Masahiro , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

Survival analysis of RRM1 and RRM2 in newly diagnosed MM patients.
Supplemental Figure 1 from Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Authors: Khagi Yulian , Goodman Aaron M. , Daniels Gregory A. , Patel Sandip P. , Sacco Assuntina G. , Randall James M. , Bazhenova Lyudmila A. , Kurzrock Razelle
Published: April 2023

S. Figure 1 PFS and OS Total Alterations
Supplementary Figure Legends from Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma
Authors: Sagawa Morihiko , Ohguchi Hiroto , Harada Takeshi , Samur Mehmet K. , Tai Yu-Tzu , Munshi Nikhil C. , Kizaki Masahiro , Hideshima Teru , Anderson Kenneth C.
Published: April 2023

Supplementary Figure Legends.
Supplemental Table 1 from Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
Authors: Monjazeb Arta M. , Kent Michael S. , Grossenbacher Steven K. , Mall Christine , Zamora Anthony E. , Mirsoian Annie , Chen Mingyi , Kol Amir , Shiao Stephen L. , Reddy Abhinav , Perks Julian R. , T.N. Culp William , Sparger Ellen E. , Canter Robert J. , Sckisel Gail D. , Murphy William J.
Published: April 2023

Table outlining patient characteristics of canine clinical trial
Supplemental Materials from Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies
Authors: Monjazeb Arta M. , Kent Michael S. , Grossenbacher Steven K. , Mall Christine , Zamora Anthony E. , Mirsoian Annie , Chen Mingyi , Kol Amir , Shiao Stephen L. , Reddy Abhinav , Perks Julian R. , T.N. Culp William , Sparger Ellen E. , Canter Robert J. , Sckisel Gail D. , Murphy William J.
Published: April 2023

Materials and Methods for flow cytometry, pcr, tissue staining, and metabolomics
Supplemental tables 1-6 and Supplemental Figure 1 from Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
Authors: Schwaederlé Maria C. , Patel Sandip P. , Husain Hatim , Ikeda Megumi , Lanman Richard B. , Banks Kimberly C. , Talasaz AmirAli , Bazhenova Lyudmila , Kurzrock Razelle
Published: April 2023

Shows the 3 ctDNA panels, the list of alterations identified, the concordance analysis for EGFR, and a diagram on response evaluation
Supplemental Data (Figures and Tables) from DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
Authors: Teo Min Yuen , Bambury Richard M. , Zabor Emily C. , Jordan Emmet , Al-Ahmadie Hikmat , Boyd Mariel E. , Bouvier Nancy , Mullane Stephanie A. , Cha Eugene K. , Roper Nitin , Ostrovnaya Irina , Hyman David M. , Bochner Bernard H. , Arcila Maria E. , Solit David B. , Berger Michael F. , Bajorin Dean F. , Bellmunt Joaquim , Iyer Gopakumar , Rosenberg Jonathan E.
Published: April 2023

Supplemental Figure 1: The association between deleterious DDR (DNA damage response and repair) alteration status as determined by in silico analysis and (A) Progression-free survival and (B) overall survival, and the association between deleterious DDR alteration status as determined by literature review, and (C) progression-free survival and (D) overall survival. DDRwt: wild type DDR; DDRalt: altered DDR not considered deleterious per methodologies employed. Supplemental Figure 2: Mutation load estimates based on MSK-IMPACT assay recapitulates whole exome sequencing data. Correlation between mutation counts generated from all sequences produced by TGCA bladder cancer whole exome sequencing and counts generated after first subsetting TCGA data to only those reads that coincide with the MSK-IMPACT capture regions. Supplemental Figure 3: (A) Mean number of total mutations, (B) number of copy number alterations and (C) fraction of copy number altered genome based on number of DNA Damage Response and Repair (DDR) alterations. (Whisker plot with Tukey method) Supplemental Figure 4: Influence of total mutation load on (A) Progression-free survival, (B) overall survival and (C) response rate. Total mutation load was divided into quartiles for the purpose of graphical representation. Supplemental Table 1: DDR Gene Panel Supplemental Table 2: All identified DDR alterations
Table S3 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary table 3 shows immunohistochemical antibodies and dilutions.
Figure S5 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary figure S5 shows PD-1+ CD4+ T cells and CD68+ macrophages are increased in SBRT-treated specimens compared to nephrectomy controls.
Cut-off determination and representative staining profiles for eIF proteins determined by immunohistochemistry from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
Authors: Humphries Matthew P. , Sundara Rajan Sreekumar , Droop Alastair , Suleman Charlotte A.B. , Carbone Carmine , Nilsson Cecilia , Honarpisheh Hedieh , Cserni Gabor , Dent Jo , Fulford Laura , Jordan Lee B. , Jones J. Louise , Kanthan Rani , Litwiniuk Maria , Di Benedetto Anna , Mottolese Marcella , Provenzano Elena , Shousha Sami , Stephens Mark , Walker Rosemary A. , Kulka Janina , Ellis Ian O. , Jeffery Margaret , Thygesen Helene H. , Cappelletti Vera , Daidone Maria G. , Hedenfalk Ingrid A. , Fjällskog Marie-Louise , Melisi Davide , Stead Lucy F. , Shaaban Abeer M. , Speirs Valerie
Published: April 2023

R.O.C curve analysis was used to determine the cut-off value for each antibody to determine a point of dichotomisation (graphs). Gradation of intensity of immunohistochemical staining (weak, moderate, strong) for eIF1 (A), eIF2 (B), eIF4E (C) and eIF5 (D) is shown in representative MBC TMA cores. Immunoreactivity is shown to the right of each R.O.C curve generated. Each core was individually scored with the proportion of tumour cells stained 0 - 4, followed by the intensity of staining 0 - 3. Combination scores reported were in the range 0 - 7. The Interclass Correlation Coefficient from scorer concordance of each biomarker was; eIF1 0.911 (95%CI 0.769-0.944), eIF2 0.846 (95%CI 0.736-0.910), eIF4E 0.882 (95%CI 0.755-0.913), eIF5 0.865 (95%CI 0.769-0.922). No staining was observed for eIF3 in MBC samples, although this was expressed in positive control tissue for EIF3, colon (E).
Figure S4 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary figure S4 shows tumors resected from RCC patients treated with SBRT have decreased CD54 and increased surface NY-ESO-1 expression.
Supplementary tables and figures legends from Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Authors: Champiat Stéphane , Dercle Laurent , Ammari Samy , Massard Christophe , Hollebecque Antoine , Postel-Vinay Sophie , Chaput Nathalie , Eggermont Alexander , Marabelle Aurélien , Soria Jean-Charles , Ferté Charles
Published: April 2023

Supplementary tables and figures legends
Supplementary Figure S1 from Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
Authors: Champiat Stéphane , Dercle Laurent , Ammari Samy , Massard Christophe , Hollebecque Antoine , Postel-Vinay Sophie , Chaput Nathalie , Eggermont Alexander , Marabelle Aurélien , Soria Jean-Charles , Ferté Charles
Published: April 2023

Figure S1 A: Distribution of the TGR EXPERIMENTAL/TGR REFERENCE ratio for HPD patients (as defined as PD estimated by the RECIST sum and TGR ratio {greater than or equal to} 2). The red dashed line represents the threshold of TGR=2 fold. Figure S1 B-F: Association between HPD and anatomo-clinical variables (B) Patterns of progression at the first tumor evaluation (N=49): Among patients with progressive disease by RECIST at the first evaluation, HPD patients exhibited a lower rate of new lesions than non-HPD progressing patients. (C) Distribution of the tumor burden at baseline (estimated by the RECIST sum) across the HPD (N=12) and the non-HPD patients (N=119) (D) Frequencies of the HPD patients among the different categories of Royal Marsden Hospital (RMH) prognostic score (E-F) Distribution of the lymphocytes (D) or LDH baseline level (E), across the HPD (N=12) and the non-HPD patients (N=119)
supplementary figures 3A and 3B from Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Authors: Vilain Ricardo E. , Menzies Alexander M. , Wilmott James S. , Kakavand Hojabr , Madore Jason , Guminski Alexander , Liniker Elizabeth , Kong Benjamin Y. , Cooper Adam J. , Howle Julie R. , Saw Robyn P.M. , Jakrot Valerie , Lo Serigne , Thompson John F. , Carlino Matteo S. , Kefford Richard F. , Long Georgina V. , Scolyer Richard A.
Published: April 2023

Gain in immune cell counts and Kaplan-Meier progression free survival curves.
Supplementary Table S1 from Pheochromocytoma: The First Metabolic Endocrine Cancer
Authors: Jochmanova Ivana , Pacak Karel
Published: April 2023

Examples of compounds with possible therapeutic effect in PHEO/PGL
Table S3 from Genome-wide DNA Methylation Analysis Reveals GABBR2 as a Novel Epigenetic Target for EGFR 19 Deletion Lung Adenocarcinoma with Induction Erlotinib Treatment
Authors: Niu Xiaomin , Liu Fatao , Zhou Yi , Zhou Zhen , Zhou Daizhan , Wang Ting , Li Ziming , Ye Xiangyun , Yu Yongfeng , Weng Xiaoling , Zhang Hong , Ye Junyi , Liao Meilin , Liu Yun , Chen Zhiwei , Lu Shun
Published: April 2023

DNA methylation results of GABAA receptor families was relatively conservative before and after erlotinib treatment in both patients using methyl-sensitive cut counting sequencing (MSCC) screening method.
Supplementary Table 2 from Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy
Authors: Bloch Orin , Lim Michael , Sughrue Michael E. , Komotar Ricardo J. , Abrahams John M. , O'Rourke Donald M. , D'Ambrosio Anthony , Bruce Jeffrey N. , Parsa Andrew T.
Published: April 2023

Characteristics of Patients with High and Low Peripheral Myeloid Cell PD-L1 Expression
Supplementary Table S7 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Supplementary Table S7
Supplementary Figure Legend from Bevacizumab Induces Acute Hypoxia and Cancer Progression in Patients with Refractory Breast Cancer: Multimodal Functional Imaging and Multiplex Cytokine Analysis
Authors: Ueda Shigeto , Saeki Toshiaki , Osaki Akihiko , Yamane Tomohiko , Kuji Ichiei
Published: April 2023

Supplementary Figure Legend
Supplementary Table S1 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Patient characteristics
Supplementary Figure legends from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Figure legends for Supplementary Fig S1-S5
Trastuzumab CRD from Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies
Authors: Spilker Mary E. , Chen Xiaoying , Visswanathan Ravi , Vage Chandra , Yamazaki Shinji , Li Gang , Lucas Judy , Bradshaw-Pierce Erica L. , Vicini Paolo
Published: April 2023

Trastuzumab CRD Calculation Details
Supplementary Fig S3 from Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer
Authors: George Julie , Saito Motonobu , Tsuta Koji , Iwakawa Reika , Shiraishi Kouya , Scheel Andreas H. , Uchida Shinsuke , Watanabe Shun-ichi , Nishikawa Ryo , Noguchi Masayuki , Peifer Martin , Jang Se Jin , Petersen Iver , Büttner Reinhard , Harris Curtis C. , Yokota Jun , Thomas Roman K. , Kohno Takashi
Published: April 2023

Genomic rearrangements described as circos plots for case 9-P from cohort 1.
Suppl. Figure 5 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

(A-B) The autophagy inhibitors intensified Taxol sensitivity in RT4 cells. Immunofluorescence for the autophagy marker LC3B was quantitated with flow cytometry. (C-D) CCK-8 was used to determine treatment effect on cell proliferation. (E-F) Restoration of REDD1 expression counteracts miR-22-mediated Taxol-induced inhibition of clone formation. T24 cells were treated with Taxol and combinations of miR-22 mimics, or REDD1 overexpression vector, or both. RT4 cells were treated with Taxol and combinations of miR-22 antagonist, or shRNA-REDD1, or both. ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05.
Suppl. Figure 3 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

miR-22 regulates cell proliferation, apoptosis, and autophagy in EJ and BIU87 cells. (A) EJ cells were transfected with miR-22 mimics, and BIU87 cells with miR-22 inhibitors and Protein expression of REDD1, C-caspase 3, c-PARP, and LC3-I/II was detected by western blot after intervention on miR-22 expression. (B) the CCK-8 method was used to detect cell proliferation. (C) Immunofluorescence for the autophagy marker LC3B was quantitated with flow cytometry. (D) The effects of miR-22 mimics or inhibitors on apoptosis of EJ or BIU87 cells were assessed through annexin V staining and flow cytometry analysis. (E) Cell cycle was analyzed by flow cytometry. ***P<0.001, **P<0.01, *P<0.05.
Suppl. Figure 2 from Inhibition of REDD1 Sensitizes Bladder Urothelial Carcinoma to Paclitaxel by Inhibiting Autophagy
Authors: Zeng Qinghai , Liu Jianye , Cao Peiguo , Li Jingjing , Liu Xiaoming , Fan Xiaojun , Liu Ling , Cheng Yan , Xiong Wei , Li Jigang , Bo Hao , Zhu Yuxing , Yang Fei , Hu Jun , Zhou Ming , Zhou Yanhong , Zou Qiong , Zhou Jianda , Cao Ke
Published: April 2023

(A) The mutation sites in the REDD1 3'UTR reporter construct. (B) The cytotoxicity test of Taxol in T24 and RT4 cells. Cell proliferation was determined in T24 and RT4 cells using the CCK-8 method.
table s3 from Evaluation of Tumor-Derived Exosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non–Small Cell Lung Cancer Using Next-Generation Sequencing
Authors: Jin Xiance , Chen Yanfan , Chen Hanbin , Fei Shaoran , Chen Didi , Cai Xiaona , Liu Linger , Lin Baochai , Su Huafang , Zhao Lihao , Su Meng , Pan Huanle , Shen Lanxiao , Xie Deyao , Xie Congying
Published: April 2023

enrichment of selected miRNAs potential target genes in oncogenesis-related pathway
Supplementary Material C from Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials
Authors: Li Daniel H. , Whitmore James B. , Guo Wentian , Ji Yuan
Published: April 2023

Supplementary Material C
Supplementary Figures 1-7 from A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non–Small Cell Lung Cancer
Authors: Gu Li , Deng Zhou J. , Roy Sweta , Hammond Paula T.
Published: April 2023

Figure S1 Assessment of the RNA loading in the LbL nanoparticles; Figure S2. MiR-34a, miR-34c, and KRAS are under-expressed in KP lung tumors than healthy lungs while CD44 is overexpressed in KP lung tumors; Figure S1 Assessment of the RNA loading in the LbL nanoparticles; Figure S3 Representative cross-section of ex vivo microCT images of lung tumors, indicated by the white nodes spread throughout the lung area; Figure S4: Physicochemical characterization of liposome/PLA/Cy5.5-labelled siRNA & RNA/PLA/HA LbL nanoparticles; Figure S5. (a) Survival rates of mice that were treated with 16 mg/kg cisplatin dosing. (b) Survival rates of mice that were treated with 8 mg/kg cisplatin dosing; Figure S6. H&E staining of kideny and liver sections of mice that received combinatory LbL nanoparticles with various cisplatin concentration; Figure S7. Serum chemistry confirmed the renal damages of the mice that received LbL nanoparticles with cisplatin dosing of 16 mg/kg and free cisplatin solution dosing of 8 mg/kg.
Supplementary Material B from Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials
Authors: Li Daniel H. , Whitmore James B. , Guo Wentian , Ji Yuan
Published: April 2023

Supplementary Material B
Supplementary Material A from Toxicity and Efficacy Probability Interval Design for Phase I Adoptive Cell Therapy Dose-Finding Clinical Trials
Authors: Li Daniel H. , Whitmore James B. , Guo Wentian , Ji Yuan
Published: April 2023

Supplementary Material A
Supplementary Figure 1A from A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer
Authors: Rosen Lee S. , Goldman Jonathan W. , Algazi Alain P. , Turner P. Kellie , Moser Brian , Hu Tianle , Wang Xuejing Aimee , Tuttle Jay , Wacheck Volker , Wooldridge James E. , Banck Michaela
Published: April 2023

Treatment duration by patient and emibetuzumab dose for emibetuzumab monotherapy (A) and emibetuzumab + erlotinib (B).
Supplementary material from Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
Authors: Baglio S. Rubina , Lagerweij Tonny , Pérez-Lanzón Maria , Ho Xuan Dung , Léveillé Nicolas , Melo Sonia A. , Cleton-Jansen Anne-Marie , Jordanova Ekaterina S. , Roncuzzi Laura , Greco Michelina , van Eijndhoven Monique A.J. , Grisendi Giulia , Dominici Massimo , Bonafede Roberta , Lougheed Sinead M. , de Gruijl Tanja D. , Zini Nicoletta , Cervo Silvia , Steffan Agostino , Canzonieri Vincenzo , Martson Aare , Maasalu Katre , Köks Sulev , Wurdinger Tom , Baldini Nicola , Pegtel D. Michiel
Published: April 2023

Supplementary figures and legends and supplementary tables
Supplementary Movie S3 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Authors: Jiao Shiping , Xia Weiya , Yamaguchi Hirohito , Wei Yongkun , Chen Mei-Kuang , Hsu Jung-Mao , Hsu Jennifer L. , Yu Wen-Hsuan , Du Yi , Lee Heng-Huan , Li Chia-Wei , Chou Chao-Kai , Lim Seung-Oe , Chang Shih-Shin , Litton Jennifer , Arun Banu , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PARPi treatment enhances resistance to activated T-cell killing. Time-lapse video of 231 (Nuc-RFP) cells without olaparib treatment (control) co-cultured with activated PBMCs taken using the IncuCyte Zoom microscope.
Supplementary Figures S1, S2, S3 and Tables S1, S2 from Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
Authors: Ma Cynthia X. , Bose Ron , Gao Feng , Freedman Rachel A. , Telli Melinda L. , Kimmick Gretchen , Winer Eric , Naughton Michael , Goetz Matthew P. , Russell Christy , Tripathy Debu , Cobleigh Melody , Forero Andres , Pluard Timothy J. , Anders Carey , Niravath Polly Ann , Thomas Shana , Anderson Jill , Bumb Caroline , Banks Kimberly C. , Lanman Richard B. , Bryce Richard , Lalani Alshad S. , Pfeifer John , Hayes Daniel F. , Pegram Mark , Blackwell Kimberly , Bedard Philippe L. , Al-Kateb Hussam , Ellis Matthew J.C.
Published: April 2023

Supplementary Figures S1, S2, S3 and Tables S1, S2
Supplementary Table and Figures from Exportin-5 Functions as an Oncogene and a Potential Therapeutic Target in Colorectal Cancer
Authors: Shigeyasu Kunitoshi , Okugawa Yoshinaga , Toden Shusuke , Boland C. Richard , Goel Ajay
Published: April 2023

Supplementary Table 1: Clinicopathological features of patients according to XPO5 expression (original validation cohort-2) Supplementary Table 2: Multivariate analysis for the predictors of disease-free survival in patients with colorectal cancer (original validation cohort-2) Supplementary Fig. 1: XPO5 expression analysis in discovery cohort. Supplementary Fig. 2: Clinicopathological significance of XPO5 expression in CRC patients Supplementary Fig. 3: The relationship between microsatellite status and XPO5 expression Supplementary Fig. 4: Intracellular localization of XPO5 Supplementary Fig. 5: pri-miRNA expression in siXPO5 CRC cells
Supplementary Tables from The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care
Authors: Paíno Teresa , Garcia-Gomez Antonio , González-Méndez Lorena , San-Segundo Laura , Hernández-García Susana , López-Iglesias Ana-Alicia , Algarín Esperanza M. , Martín-Sánchez Montserrat , Corbacho David , Ortiz-de-Solorzano Carlos , Corchete Luis A. , Gutiérrez Norma C. , Maetos María-Victoria , Garayoa Mercedes , Ocio Enrique M.
Published: April 2023

-Supplementary Table 1. Combination indices (CI) corresponding to the indicated double or triple combinations of PIM447, bortezomib and dexamethasone. -Supplementary Table 2. Combination indices (CI) corresponding to the indicated double or triple combinations of PIM447, lenalidomide and dexamethasone. -Supplementary Table 3. Combination indices (CI) corresponding to the indicated double or triple combinations of PIM447, pomalidomide and dexamethasone.
Supplementary Table S3 from Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RETM918T Tumors
Authors: Mancikova Veronika , Montero-Conde Cristina , Perales-Paton Javier , Fernandez Agustin , Santacana María , Jodkowska Karolina , Inglada-Pérez Lucia , Castelblanco Esmeralda , Borrego Salud , Encinas Mario , Matias-Guiu Xavier , Fraga Mario , Robledo Mercedes
Published: April 2023

Primers used in the study.
Supplemental Tables from Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells
Authors: Patel Viralkumar , Balakrishnan Kumudha , Bibikova Elena , Ayres Mary , Keating Michael J. , Wierda William G. , Gandhi Varsha
Published: April 2023

Supplemental Table 1. Patient samples and their cytogenetic features and prognostic markers. Supplemental Table 2. Antibodies for immunoblots and their sources
Supplementary Table S3 from Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma
Authors: Kang Hyunseok , Tan Marietta , Bishop Justin A. , Jones Siân , Sausen Mark , Ha Patrick K. , Agrawal Nishant
Published: April 2023

Supplementary Table S3 contains information on the clinical characteristics and mutational landscapes of MEC tumors of varying histologic grades.
Supplementary Figure S6 from Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia
Authors: Amin Nisar A. , Balasubramanian Sriram , Saiya-Cork Kamlai , Shedden Kerby , Hu Nan , Malek Sami N.
Published: April 2023

Effects of TP53 disruption on BCR signaling in the B- lymphoblastoid cell line PG-EBV:
Supplementary Table S2 from Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma
Authors: Kang Hyunseok , Tan Marietta , Bishop Justin A. , Jones Siân , Sausen Mark , Ha Patrick K. , Agrawal Nishant
Published: April 2023

Supplementary Table S2 provides a comprehensive list of somatic mutations identified via whole-exome sequencing in 18 MEC tumor samples.
Supplementary Table S1 from Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma
Authors: Kang Hyunseok , Tan Marietta , Bishop Justin A. , Jones Siân , Sausen Mark , Ha Patrick K. , Agrawal Nishant
Published: April 2023

Supplementary Table S1 provides a summary of the whole-exome sequencing analysis for normal and tumor samples.
Supplementary Figure S1 from Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma
Authors: Kang Hyunseok , Tan Marietta , Bishop Justin A. , Jones Siân , Sausen Mark , Ha Patrick K. , Agrawal Nishant
Published: April 2023

Figure S1 contains representative images of cells with and without the MECT1-MAML2 translocation, as determined by fluorescence in situ hybridization.
Supplemental Table 1 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

Clinicopathological characteristics of the CONFIRM study patients and transCONFIRM cohort
Supplementary tables from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Supplementary Table 1. Clinical information for seven paired samples of ESCC verus adjacent noncancerous tissues with lncRNA and microRNA microarray analysis Supplementary Table 2. The annotation of probes name Supplementary Table 3. The strong correlation between miRNAs and lncRNAs Supplementary Table 4. LncRNA-TTN-AS1 expression and clinicopathological features in patients with esophageal squamous cell carcinoma Supplementary Table 5. MiR-133b expression and clinicopathological features in patients with esophageal squamous cell carcinoma Supplementary Table 6. FSCN1 expression and clinicopathological features in patients with esophageal squamous cell carcinoma Supplementary Table 7. LncRNA-TTN-AS1 expression and clinicopathological features in patients with esophageal squamous cell carcinoma Supplementary Table 8. MiR-133b expression and clinicopathological features in patients with esophageal squamous cell carcinoma Supplementary Table 9. FSCN1 expression and clinicopathological features in patients with esophageal squamous cell carcinoma Supplementary Table 10. Univariate and Multivariate Cox Regression Analyses of potential factors for survival in ESCC patients Supplementary Table 11. Primer sequence used in the research
Supplemental Figure 3 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

PFS and OS of PAM50 and OncotypeDx risk categories
Supplemental Figure 2 from TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor–Positive Breast Cancer
Authors: Jeselsohn Rinath , Barry William T. , Migliaccio Ilenia , Biagioni Chiara , Zhao Jin , De Tribolet-Hardy Jonas , Guarducci Cristina , Bonechi Martina , Laing Naomi , Winer Eric P. , Brown Myles , Leo Angelo Di , Malorni Luca
Published: April 2023

Correlation between IHC and transcript level by microarray
Supplementary Figure S7. from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

LncRNA-TTN-AS1 promotes EMT and abrogates the effects of miR-133b.
Supplementary Figure S6 from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

LncRNA-TTN-AS1 induces ESCC cell proliferation and metastasis.
Supplementary Figure S5. from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Modulation of Snail1 by lncRNA-TTN-AS1.
Supplemental Figure 5 from CTLA-4 Limits Anti-CD20–Mediated Tumor Regression
Authors: Ren Zhenhua , Guo Jingya , Liao Jing , Luan Yan , Liu Zhida , Sun Zhichen , Liu Xiaojuan , Liang Yong , Peng Hua , Fu Yang-Xin
Published: April 2023

Supplementary Figure 5. FTY720 could efficiently prohibit lymphocytes from exiting the lymphoid organ.
Supplementary Figure S3. from Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis
Authors: Lin Chenyu , Zhang Shengnan , Wang Ying , Wang Yuanshu , Nice Edouard , Guo Changying , Zhang Erhao , Yu Liting , Li Mengwei , Liu Chen , Hu Lirong , Hao Jingchao , Qi Weiyan , Xu Hanmei
Published: April 2023

Negative correlation between lncRNA-TTN-AS1 and miR-133b in ESCC tissues and cell lines.
Table S2. Vaccine response-associated genes identified by the Combined Multivariate and Collapsing method. from PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer
Authors: Qian David C. , Xiao Xiangjun , Byun Jinyoung , Suriawinata Arief A. , Her Stephanie C. , Amos Christopher I. , Barth Richard J.
Published: April 2023

Vaccine response-associated genes identified by the Combined Multivariate and Collapsing method.
Figure S1 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

KRAS mutations enhance transformation in METex14 cells
Supplementary Data from Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Authors: Kato Shumei , Okamura Ryosuke , Baumgartner Joel M. , Patel Hitendra , Leichman Lawrence , Kelly Kaitlyn , Sicklick Jason K. , Fanta Paul T. , Lippman Scott M. , Kurzrock Razelle
Published: April 2023

Supplementary Data
Supplementary Methods from Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients
Authors: Richard Corentin , Fumet Jean-David , Chevrier Sandy , Derangère Valentin , Ledys Fanny , Lagrange Aurélie , Favier Laure , Coudert Bruno , Arnould Laurent , Truntzer Caroline , Boidot Romain , Ghiringhelli François
Published: April 2023

Supplementary Methods